Post-polycythemia Vera Myelofibrosis Clinical Trials

52 clinical trials for Post-polycythemia Vera Myelofibrosis across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms — RECRUITING · PHASE1
• A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) — RECRUITING · PHASE3
• Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis — RECRUITING · PHASE1
• Research Platform Myelofibrosis and Anemia — RECRUITING
• Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) — RECRUITING · PHASE1
• A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) — RECRUITING · PHASE1
• A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) — RECRUITING · PHASE3
• MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) — RECRUITING
• A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis — RECRUITING
• Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition — RECRUITING · PHASE1
• Asian Myeloproliferative Neoplasm (MPN) Registry — RECRUITING
• A RANDOMIZED, CONTROLLED PHASE 3 STUDY OF PACRITINIB VERSUS PHYSICIAN'S CHOICE IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA (PLATELETS COUNTS <50,000/MCL) — RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE ACTIVITY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC, ANEMIC SUBJECTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA (PV) MYELOFIBROSIS, OR POST ESSENTIAL THROMBOCYTHEMIA (ET) MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH JAK INHIBITOR THERAPY — RECRUITING · PHASE3
• A RANDOMIZED CONTROLLED PHASE 3 STUDY OF ORAL PACRITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH THROMBOCYTOPENIA AND PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS. — RECRUITING · PHASE3
• Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis — COMPLETED · PHASE1
• Revumenib in Patients With Myelofibrosis — NOT_YET_RECRUITING · PHASE1
• Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) — ACTIVE_NOT_RECRUITING · PHASE3
• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions — ACTIVE_NOT_RECRUITING · PHASE3
• Extended Access of Momelotinib in Adults With Myelofibrosis — ACTIVE_NOT_RECRUITING · PHASE2
• Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors — TERMINATED · PHASE2
• INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — ACTIVE_NOT_RECRUITING · PHASE3
• Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias — NOT_YET_RECRUITING · PHASE2
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) — TERMINATED · PHASE3
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) — TERMINATED · PHASE3
• Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis — TERMINATED · PHASE2
• A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib — TERMINATED · PHASE3
• Real World Evidence of Fedratinib Effectiveness in MF — OTHER
• Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) — COMPLETED · PHASE1
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) — COMPLETED · PHASE3
• A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis — COMPLETED
• A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia — WITHDRAWN · PHASE1
• Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia — COMPLETED · PHASE2
• Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis — COMPLETED · PHASE3
• Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis — COMPLETED · PHASE2
• MPN-RC 118 AVID200 in Myelofibrosis — COMPLETED · PHASE1
• Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib — TERMINATED · PHASE1
• Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis — TERMINATED · PHASE1
• Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib — COMPLETED · PHASE2
• Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis — OTHER · PHASE2
• Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF — COMPLETED · PHASE1
• Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia — TERMINATED · PHASE3
• Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis — COMPLETED · PHASE1
• Study of Select Combinations in Adults With Myelofibrosis — WITHDRAWN · PHASE1
• Pacritinib Versus Best Available Therapy to Treat Myelofibrosis — TERMINATED · PHASE3
• Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. — COMPLETED · PHASE2
• Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis — COMPLETED · PHASE2
• Ruxolitinib Prior to Transplant in Patients With Myelofibrosis — TERMINATED · PHASE2
• Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) — COMPLETED · PHASE2
• Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) — COMPLETED · PHASE1

Refine this search